- Home
- ABEO vs MTLS Comparison
ABEO vs MTLS Comparison
Compare ABEO & MTLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ABEO | MTLS |
|---|---|---|
| Founded | 1974 | 1990 |
| Country | United States | Belgium |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Computer Software: Prepackaged Software |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 399.5M | 431.6M |
| IPO Year | 2005 | 2014 |
Fundamental Metrics
Financial Performance| Metric | ABEO | MTLS |
|---|---|---|
| Price | $4.90 | $8.27 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 7 | 3 |
| Target Price | ★ $18.88 | $8.80 |
| AVG Volume (30 Days) | ★ 1.3M | 219.0K |
| Earning Date | 11-11-2026 | 10-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 165.16 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,998,000.00 | N/A |
| Revenue This Year | $804.33 | $3.97 |
| Revenue Next Year | $119.68 | $5.95 |
| P/E Ratio | ★ N/A | $61.39 |
| Revenue Growth | ★ 258.18 | N/A |
| 52 Week Low | $4.00 | $4.78 |
| 52 Week High | $7.65 | $8.82 |
Technical Indicators
Market Signals| Indicator | ABEO | MTLS |
|---|---|---|
| Relative Strength Index (RSI) | 32.84 | 58.74 |
| Support Level | $4.23 | $6.37 |
| Resistance Level | $5.36 | $8.82 |
| Average True Range (ATR) | 0.19 | 0.26 |
| MACD | -0.01 | -0.05 |
| Stochastic Oscillator | 5.74 | 46.63 |
Price Performance
Historical ComparisonAbout ABEO Abeona Therapeutics Inc.
Abeona Therapeutics Inc is a commercial-stage biopharmaceutical company. The company is focused on developing cell and gene therapies for life-threatening diseases. The company's ZEVASKYN (prademagene zamikeracel) is an autologous cell-based gene therapy for the treatment of wounds in adults and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB). The company's development portfolio includes adeno-associated virus (AAV)-based gene therapies for ophthalmic diseases with high unmet medical need.
About MTLS Materialise NV
Materialise NV is a provider of 3D-printed medical devices and software and a pioneer in additive manufacturing software and services. The company operates through three principal segments: Materialise Software, Materialise Medical, and Materialise Manufacturing, with the Materialise Medical segment generating maximum revenue. The Materialise Medical segment develops and delivers medical software solutions, medical devices, and related products and services; the Materialise Software segment develops and delivers additive manufacturing software solutions and related services; and the Materialise Manufacturing segment delivers 3D-printed products and related services. The company generates maximum revenue from the United States of America.